A U.S. judge said on Tuesday that Novo Nordisk must face part of a lawsuit accusing it of defrauding shareholders about a clinical trial for its weight loss and diabetes treatment CagriSema. Novo Nordisk had no immediate comment. Novo Nordisk’s U.S. headquarters are in Plainsboro, New Jersey. CagriSema combined semaglutide, the active ingredient in Novo Nordisk’s Wegovy, with the molecule cagrilintide, which mimics the pancreatic hormone amylin. Investors and analysts hoped the trial, known as Redefine 1, would show Novo Nordisk had a strong pipeline of anti-obesity drugs to follow Wegovy.